Stockreport

Jefferies starts Nuvalent at buy, cites lung cancer drug candidates [Seeking Alpha]

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF The investment firm sees zidesamtinib, also known as NVL-520, potentially generating adjusted peak sales of around $1.7B in the treatment of ROS1+ NSCLC and NVL-655 wit [Read more]